Optimizing Long-Term Management of Chronic Heart Failure: An Expert Consensus on the Evolving Role of Ivabradine

Abstract

Persistent sinus tachycardia contributes to the progression of chronic Heart Failure (HF) and remains an important modifiable therapeutic target despite the widespread use of contemporary quadruple Guideline-Directed Medical Therapy (GDMT). Ivabradine, a selective inhibitor of the sinus node If current, effectively lowers resting Heart Rate (HR) without exerting negative inotropic or hypotensive effects. Evidence from the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT) and subsequent meta-analyses has demonstrated significant long-term clinical benefits, including an 18% relative reduction in the composite of cardiovascular death or first HF hospitalization and a 26% reduction in HF-related hospitalizations, with greater benefit observed in patients achieving larger reductions in HR. Long-term registry data and extension studies further support the durability of ivabradine therapy, demonstrating sustained HR reductions of 10-25 beats/min, persistent improvement in New York Heart Association (NYHA) functional class and treatment persistence exceeding 80% over three years or longer. The development of a once-daily prolonged-release formulation, which is pharmacokinetically bioequivalent to the conventional twice-daily immediate-release formulation, provides comparable HR-lowering efficacy while reducing pill burden and potentially enhancing long-term adherence. Ivabradine can be safely combined with other components of GDMT, including sacubitril/valsartan, mineralocorticoid receptor antagonists and sodium-glucose cotransporter-2 inhibitors, as it has no clinically relevant drug-drug interactions with these therapies. Clinical trials and real-world studies have consistently demonstrated a favorable safety profile, with infrequent reports of luminous visual phenomena, a low incidence of new-onset atrial fibrillation and a minimal risk of reversible bradycardia. The greatest benefit is observed in patients with sinus rhythm and a resting HR >70 beats/min despite receiving maximally tolerated β-blocker therapy or in those who are unable to tolerate β-blockers. Emerging evidence also suggests a potential role for ivabradine in device optimization and selected cases of acute decompensated HF. Despite the growing body of evidence supporting its efficacy and safety, uncertainties remain regarding the optimal long-term positioning of ivabradine in HF management, particularly in routine clinical practice. To address this gap, five focused group discussions involving 60 leading cardiologists across India were conducted to capture expert perspectives on the long-term management of HF and the evolving role of ivabradine. This review integrates current scientific evidence with these expert insights to define the role of once-daily ivabradine as a hemodynamically neutral, heart rate-selective adjunct that provides sustained symptomatic and prognostic benefits, thereby reinforcing its value in the lifelong management of patients with tachycardic heart failure.